ABSTRACT
Introduction: Transcatheter aortic valves have evolved over the last 15 years. Second- and third- generation devices have considerably improved, and a range of newer devices have also been introduced with the aim of decreasing the incidence of paravalvular leak, reducing the need for permanent pacemaker implantation and minimizing procedure- and device-related complications.
Areas covered: In this review, we highlight the special features of the latest generation of self-expanding Evolut PRO (Medtronic, Minneapolis, Minnesota) transcatheter aortic valve system. A detailed literature search on the Medtronic Evolut R and Evolut PRO transcatheter aortic valves was undertaken using Ovid, PubMed and Web of Science.
Expert commentary: In a single, small study, the Evolut PRO has shown significant improvement over the Evolut R in terms of reduced paravalvular leak and pacemaker implantation. Larger scaled studies are needed to ascertain the performance of the Evolut PRO.
Acknowledgments
The authors want to thank Aida Cucui, MD, CCRP, Sr. Clinical Research Specialist, Medtronic, Canada, for her help in providing the images.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
One peer reviewer is on the executive committee for Corevalve IDE trials, SURTAVI and Evolut low risk, is a national surgical investigator on SURTAVI and Evolut Low risk, and an author and investigator for the Evolut Pro trial. One peer reviewer is a proctor for Medtronic CoreValve, Evolut R and Pro valves. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.